Updated Analysis of Treatment Outcomes with Temozolomide Plus Capecitabine in Patients with Pancreatic Neuroendocrine Tumors in Japan

Updated Analysis of Treatment Outcomes with Temozolomide Plus Capecitabine in Patients with Pancreatic Neuroendocrine Tumors in Japan - JON2305-N

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000057588

Enrollment

106

Registered

2025-04-11

Start date

2025-03-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic neuroendocrine tumors

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients with pancreatic neuroendocrine tumors* who received CAPTEM therapy at participating institutions. *Pancreatic neuroendocrine tumors include NET (neuroendocrine tumor), NEC (neuroendocrine carcinoma), and MiNEN (mixed neuroendocrine-non-neuroendocrine neoplasm). 2)Patients who initiated the therapy between January 1, 2008, and December 31, 2023. 3)Patients enrolled in the Usage Survey 2018 (A Survey on the Use of Temozolomide plus Capecitabine Therapy for Pancreatic Neuroendocrine Tumors).

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Objective response rate (RECIST version 1.1)	—

Secondary

Measure	Time frame
Disease control rate, progression-free survival, overall survival, adverse events, and serious adverse events (CTCAE version 5.0)	—

Countries

Japan

Contacts

Public ContactKanae Inoue

National Cancer Center Hospital East Department of Hepatobiliary and Pancreatic Oncology

kaninoue@east.ncc.go.jp04-7133-1111

Outcome results